Neurologic complications after chlorhexidine antisepsis for spinal anesthesia

Hans P. Sviggum, Adam K. Jacob, Katherine W. Arendt, Michelle M Mauermann, Terese T. Horlocker, James R. Hebl

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background and Objectives: Recent reports of infectious complications after neuraxial procedures highlight the importance of scrupulous aseptic technique. Although chlorhexidine gluconate (CHG) has several advantages over other antiseptic agents; including a more rapid onset of action, an extended duration of effect, and rare bacterial resistance, it is not approved by the US Food and Drug Administration for use before lumbar puncture because of absence of clinical safety evidence. The objective of this retrospective cohort study was to test the hypothesis that the incidence of neurologic complications associated with spinal anesthesia after CHG skin antisepsis is not different than the known incidence of neurologic complications associated with spinal anesthesia. Methods: All patients 18 years or older who underwent spinal anesthesia at Mayo Clinic Rochester from 2006 to 2010 were identified. The primary outcome variable was the presence of any new or progressive neurologic deficit documentedwithin 7 days of spinal anesthesia. The etiology of a patient's neurologic complication was independently categorized as possibly or unlikely related to the spinal anesthetic by 3 investigators. Consensus among all reviewers was required for final category assignment. Results: A total of 11,095 patients received 12,465 spinal anesthetics during the study period. Overall, 57 cases (0.46%; 95% confidence interval, 0.34%-0.58%) met criteria for neurologic complication. Spinal anesthesia was felt to be the possible etiology of 5 neurologic complications (0.04%; 95% confidence interval, 0.00%-0.08%); all completely resolved within 30 days. Discussion: The incidence of neurologic complications possibly associated with spinal anesthesia (0.04%) after CHG skin antisepsis is consistent with previous reports of neurologic complications after spinal anesthesia. These results support the hypothesis that CHG can be used for skin antisepsis before spinal placement without increasing the risk of neurologic complications attributed to the spinal anesthetic.

Original languageEnglish (US)
Pages (from-to)139-144
Number of pages6
JournalRegional Anesthesia and Pain Medicine
Volume37
Issue number2
DOIs
StatePublished - Mar 2012

Fingerprint

Antisepsis
Chlorhexidine
Spinal Anesthesia
Nervous System
Anesthetics
Skin
Incidence
Confidence Intervals
Local Anti-Infective Agents
Spinal Puncture
United States Food and Drug Administration
Neurologic Manifestations
Cohort Studies
Retrospective Studies
Research Personnel
Safety

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Neurologic complications after chlorhexidine antisepsis for spinal anesthesia. / Sviggum, Hans P.; Jacob, Adam K.; Arendt, Katherine W.; Mauermann, Michelle M; Horlocker, Terese T.; Hebl, James R.

In: Regional Anesthesia and Pain Medicine, Vol. 37, No. 2, 03.2012, p. 139-144.

Research output: Contribution to journalArticle

Sviggum, Hans P. ; Jacob, Adam K. ; Arendt, Katherine W. ; Mauermann, Michelle M ; Horlocker, Terese T. ; Hebl, James R. / Neurologic complications after chlorhexidine antisepsis for spinal anesthesia. In: Regional Anesthesia and Pain Medicine. 2012 ; Vol. 37, No. 2. pp. 139-144.
@article{ee1819fde3314e0b97de39aa54ab0bd8,
title = "Neurologic complications after chlorhexidine antisepsis for spinal anesthesia",
abstract = "Background and Objectives: Recent reports of infectious complications after neuraxial procedures highlight the importance of scrupulous aseptic technique. Although chlorhexidine gluconate (CHG) has several advantages over other antiseptic agents; including a more rapid onset of action, an extended duration of effect, and rare bacterial resistance, it is not approved by the US Food and Drug Administration for use before lumbar puncture because of absence of clinical safety evidence. The objective of this retrospective cohort study was to test the hypothesis that the incidence of neurologic complications associated with spinal anesthesia after CHG skin antisepsis is not different than the known incidence of neurologic complications associated with spinal anesthesia. Methods: All patients 18 years or older who underwent spinal anesthesia at Mayo Clinic Rochester from 2006 to 2010 were identified. The primary outcome variable was the presence of any new or progressive neurologic deficit documentedwithin 7 days of spinal anesthesia. The etiology of a patient's neurologic complication was independently categorized as possibly or unlikely related to the spinal anesthetic by 3 investigators. Consensus among all reviewers was required for final category assignment. Results: A total of 11,095 patients received 12,465 spinal anesthetics during the study period. Overall, 57 cases (0.46{\%}; 95{\%} confidence interval, 0.34{\%}-0.58{\%}) met criteria for neurologic complication. Spinal anesthesia was felt to be the possible etiology of 5 neurologic complications (0.04{\%}; 95{\%} confidence interval, 0.00{\%}-0.08{\%}); all completely resolved within 30 days. Discussion: The incidence of neurologic complications possibly associated with spinal anesthesia (0.04{\%}) after CHG skin antisepsis is consistent with previous reports of neurologic complications after spinal anesthesia. These results support the hypothesis that CHG can be used for skin antisepsis before spinal placement without increasing the risk of neurologic complications attributed to the spinal anesthetic.",
author = "Sviggum, {Hans P.} and Jacob, {Adam K.} and Arendt, {Katherine W.} and Mauermann, {Michelle M} and Horlocker, {Terese T.} and Hebl, {James R.}",
year = "2012",
month = "3",
doi = "10.1097/AAP.0b013e318244179a",
language = "English (US)",
volume = "37",
pages = "139--144",
journal = "Regional Anesthesia and Pain Medicine",
issn = "1098-7339",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Neurologic complications after chlorhexidine antisepsis for spinal anesthesia

AU - Sviggum, Hans P.

AU - Jacob, Adam K.

AU - Arendt, Katherine W.

AU - Mauermann, Michelle M

AU - Horlocker, Terese T.

AU - Hebl, James R.

PY - 2012/3

Y1 - 2012/3

N2 - Background and Objectives: Recent reports of infectious complications after neuraxial procedures highlight the importance of scrupulous aseptic technique. Although chlorhexidine gluconate (CHG) has several advantages over other antiseptic agents; including a more rapid onset of action, an extended duration of effect, and rare bacterial resistance, it is not approved by the US Food and Drug Administration for use before lumbar puncture because of absence of clinical safety evidence. The objective of this retrospective cohort study was to test the hypothesis that the incidence of neurologic complications associated with spinal anesthesia after CHG skin antisepsis is not different than the known incidence of neurologic complications associated with spinal anesthesia. Methods: All patients 18 years or older who underwent spinal anesthesia at Mayo Clinic Rochester from 2006 to 2010 were identified. The primary outcome variable was the presence of any new or progressive neurologic deficit documentedwithin 7 days of spinal anesthesia. The etiology of a patient's neurologic complication was independently categorized as possibly or unlikely related to the spinal anesthetic by 3 investigators. Consensus among all reviewers was required for final category assignment. Results: A total of 11,095 patients received 12,465 spinal anesthetics during the study period. Overall, 57 cases (0.46%; 95% confidence interval, 0.34%-0.58%) met criteria for neurologic complication. Spinal anesthesia was felt to be the possible etiology of 5 neurologic complications (0.04%; 95% confidence interval, 0.00%-0.08%); all completely resolved within 30 days. Discussion: The incidence of neurologic complications possibly associated with spinal anesthesia (0.04%) after CHG skin antisepsis is consistent with previous reports of neurologic complications after spinal anesthesia. These results support the hypothesis that CHG can be used for skin antisepsis before spinal placement without increasing the risk of neurologic complications attributed to the spinal anesthetic.

AB - Background and Objectives: Recent reports of infectious complications after neuraxial procedures highlight the importance of scrupulous aseptic technique. Although chlorhexidine gluconate (CHG) has several advantages over other antiseptic agents; including a more rapid onset of action, an extended duration of effect, and rare bacterial resistance, it is not approved by the US Food and Drug Administration for use before lumbar puncture because of absence of clinical safety evidence. The objective of this retrospective cohort study was to test the hypothesis that the incidence of neurologic complications associated with spinal anesthesia after CHG skin antisepsis is not different than the known incidence of neurologic complications associated with spinal anesthesia. Methods: All patients 18 years or older who underwent spinal anesthesia at Mayo Clinic Rochester from 2006 to 2010 were identified. The primary outcome variable was the presence of any new or progressive neurologic deficit documentedwithin 7 days of spinal anesthesia. The etiology of a patient's neurologic complication was independently categorized as possibly or unlikely related to the spinal anesthetic by 3 investigators. Consensus among all reviewers was required for final category assignment. Results: A total of 11,095 patients received 12,465 spinal anesthetics during the study period. Overall, 57 cases (0.46%; 95% confidence interval, 0.34%-0.58%) met criteria for neurologic complication. Spinal anesthesia was felt to be the possible etiology of 5 neurologic complications (0.04%; 95% confidence interval, 0.00%-0.08%); all completely resolved within 30 days. Discussion: The incidence of neurologic complications possibly associated with spinal anesthesia (0.04%) after CHG skin antisepsis is consistent with previous reports of neurologic complications after spinal anesthesia. These results support the hypothesis that CHG can be used for skin antisepsis before spinal placement without increasing the risk of neurologic complications attributed to the spinal anesthetic.

UR - http://www.scopus.com/inward/record.url?scp=84859761478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859761478&partnerID=8YFLogxK

U2 - 10.1097/AAP.0b013e318244179a

DO - 10.1097/AAP.0b013e318244179a

M3 - Article

C2 - 22286519

AN - SCOPUS:84859761478

VL - 37

SP - 139

EP - 144

JO - Regional Anesthesia and Pain Medicine

JF - Regional Anesthesia and Pain Medicine

SN - 1098-7339

IS - 2

ER -